Global Photopheresis Devices Market – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024
Global Photopheresis Devices Market: By Product Type (Open System, Closed System), By Disease Indication (Autoimmune diseases, Graft versus host disease, Cutaneous T-cell lymphoma, Transplant rejections), By Distribution Channel (Hospitals, Ambulatory Care, Others), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024
Global photopheresis devices market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over the 2018 to 2024.
Market Outline: Photopheresis Devices Market
Photopheresis is a form of apheresis in which small amount of the blood is treated with photosensitizing agent. Photopheresis is popular for its therapeutic option used in various autoimmune diseases, organ transplantation such as kidney and liver advanced cutaneous T-cell lymphoma and acute and chronic graft versus host disease (GVHD). U.S. FDA in 1988, has first approved extracorporeal photopheresis (ECP) which is now known as extracorporeal photo immunotherapy, as leukapheresis-based therapeutic procedure. In Photopheresis, the white blood cells are collected after being exposed to the UVA radiation, 8-MOP. As far as devices of photopheresis are concerned, many open and closed systems available in the market, of which only closed systems are approved by the U.S. FDA due to its lesser risk of contamination, flaws and infection during reinfusion.
Market Dynamics: Photopheresis Devices Market
The increasing prevalence of autoimmune diseases and rising number of organ transplant cases are expected to drive the photopheresis devices market. The safer and effective treatment promised by the introduction of these devices is one of the major factor expected to drives photopheresis devices market. The increased government reimbursement policies and private health insurance is playing a key role in the growth of the market. The awareness about ECP therapy will boost the market. However, the higher cost, time, constant therapy sessions are expected to hinder the market. The availability of lesser number of ECP therapy centers is expected to dampen the market.
Free sample of this report is available upon request @
Market Scope: Photopheresis Devices Market
Photopheresis devices market is segmented based on the product type, technology, disease indication, and distribution channel
Based on the product type, the market is segmented into the following:
- Open System
- Closed system
Based on the disease indication, the market is segmented into the following:
- Autoimmune diseases
- Graft versus host disease
- Cutaneous T-cell lymphoma
- Transplant rejections
Based on the distribution channel, the market is segmented into the following:
- Hospitals
- Ambulatory Surgical Centers
- Others
Free TOC of this report is available upon request @
Regional Analysis: Photopheresis Devices Market
Geographically, global photopheresis devices market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America photopheresis devices market is dominant in the photopheresis devices market. The huge reimbursements provided by the government for various treatments such as GVHD, CTL, and lung transplantations which is treated by ECP therapy is a key factor expected to drive the market. However, Asia Pacific is expected to dominate the market due to increased initiatives in terms of the expansion of the photopheresis products market over the forecast period. The increasing count of photopheresis centers is expected to drive the market. The faster regulatory approvals is expected fuel the market in future.
Need more information about this report @
Competition Assessment: Photopheresis Devices Market
Some of the players in the global photopheresis devices market include:
- Macopharma (FRANCE)
- Haemonetics Corporation (U.S)
- Fresenius Kabi AG (Germany)
- Terumo Corporation (Japan)
- Mallinckrodt Pharmaceuticals (UK)
Notable Market Developments: Photopheresis Devices Market
- In August 2016, Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, announced that Switzerland’s Federal Department of Home Affairs (FDHA) has approved reimbursement of Extracorporeal Photopheresis (ECP) treatment for patients in Switzerland with Bronchiolitis Obliterans Syndrome (BOS) following lung transplantation. Mallinckrodt Pharmaceuticals provides ECP therapy through its THERAKOS therapeutic platforms, including the latest generation THERAKOS CELLEX Photopheresis System.
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/photopheresis-devices-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US):+1-866-598-1553
Website @https://www.precisionbusinessinsights.com